NSD3 protein methylation and stabilization transforms human ES cells into variant state DOI Creative Commons
Vignesh K Krishnamoorthy,

Fariha Hamdani,

Pooja Shukla

et al.

Life Science Alliance, Journal Year: 2024, Volume and Issue: 8(3), P. e202402871 - e202402871

Published: Dec. 31, 2024

Cultured human embryonic stem cells (hESCs) can develop genetic anomalies that increase their susceptibility to transformation. In this study, we characterized a variant hESC (vhESC) line and investigated the molecular mechanisms leading drift towards transformed state. Our findings revealed vhESCs up-regulate EMT-specific markers, accelerate wound healing, exhibit compromised lineage differentiation, retain pluripotency gene expression in teratomas. Furthermore, discovered an altered epigenomic landscape overexpression of lysine methyltransferases EHMT1, EHMT2, NSD group proteins vhESCs. Remarkably, depleting NSD3 oncogene reversed phenotypic changes We identified detailed mechanism where EHMT2 interacts methylates at 477, stabilizing its protein levels addition, showed are regulated by degradation hESCs, stabilization leads emergence Overall, our study identify misregulation pluripotent cells, through methylation-mediated abrogation degradation, drives hESCs oncogenic

Language: Английский

Omics Technologies Improving Breast Cancer Research and Diagnostics DOI Open Access

Arianna Orsini,

Chiara Diquigiovanni, Elena Bonora

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(16), P. 12690 - 12690

Published: Aug. 11, 2023

Breast cancer (BC) has yielded approximately 2.26 million new cases and caused nearly 685,000 deaths worldwide in the last two years, making it most common diagnosed type world. BC is an intricate ecosystem formed by both tumor microenvironment malignant cells, its heterogeneity impacts response to treatment. Biomedical research entered era of massive omics data thanks high-throughput sequencing revolution, quick progress widespread adoption. These technologies—liquid biopsy, transcriptomics, epigenomics, proteomics, metabolomics, pharmaco-omics artificial intelligence imaging—could help researchers clinicians better understand formation evolution BC. This review focuses on findings recent multi-omics-based that been applied research, with introduction every technique their applications for different phenotypes, biomarkers, target therapies, diagnosis, treatment prognosis, provide a comprehensive overview possibilities research.

Language: Английский

Citations

19
Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy DOI Creative Commons
Yue Shen,

Jie-Qi Chen,

Xiangping Li

et al.

Genes & Diseases, Journal Year: 2024, Volume and Issue: 12(3), P. 101374 - 101374

Published: July 11, 2024

With the rapid advancements in second-generation gene sequencing technologies, a growing number of driver genes and associated therapeutic targets have been unveiled for lung adenocarcinoma (LUAD) squamous cell carcinoma (LUSC). While they are clinically classified as non-small cancer (NSCLC), display distinct genomic features substantial variations clinical efficacy, underscoring need particular attention. Hence, this review provides comprehensive overview latest genes, epigenetic targets, chemotherapy, targeted therapy, immunotherapy LUAD LUSC. Additionally, it delves into distinctions signaling pathways pivotal facets management specific to these two categories cancer. Moreover, we furnish pertinent details regarding trials pertaining epigenetics, thus establishing theoretical foundation realization precision treatments

Language: Английский

Citations

5
Epigenetic Regulation of Fungal Secondary Metabolism DOI Creative Commons
Yufei Zhang, Wenbin Yu, Yi Lü

et al.

Journal of Fungi, Journal Year: 2024, Volume and Issue: 10(9), P. 648 - 648

Published: Sept. 13, 2024

Secondary metabolism is one of the important mechanisms by which fungi adapt to their living environment and promote survival reproduction. Recent studies have shown that epigenetic regulation, such as DNA methylation, histone modifications, non-coding RNAs, plays key roles in fungal secondary affect growth, survival, pathogenicity. This review describes recent advances study regulation metabolism. We discuss way markers respond environmental changes stimulate production biologically active compounds fungi, feasibility these new findings applied develop antifungal strategies optimize In addition, we deliberated on possible future directions research this field. A deeper understanding regulatory networks a focus for research.

Language: Английский

Citations

5
Design, Synthesis, and Antitumor Activity of NSDs Inhibitors Targeting Lung Squamous Cell Carcinoma DOI
Siyu Xiu, Zhenyu Jia, Zhiqi Wang

et al.

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 289, P. 117388 - 117388

Published: Feb. 13, 2025

Language: Английский

Citations

0
Landscape of targeted therapies for lung squamous cell carcinoma DOI Creative Commons

Qiuxuan Chen,

Xiao-Shuo Zheng,

Weiting Cheng

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 31, 2024

Lung cancer, a common type of malignant neoplasm, has seen significant advancements in the treatment lung adenocarcinoma (LUAD). However, management squamous cell carcinoma (LSCC) continues to pose challenges. Traditional methods for LSCC encompass surgical resection, chemotherapy, and radiotherapy. The introduction targeted therapy immunotherapy greatly benefited patients, but issues such as limited immune response rates adverse reactions persist. Therefore, gaining deeper comprehension underlying mechanisms holds immense importance. This review provides an in-depth overview classical signaling pathways therapeutic targets, including PI3K pathway, CDK4/6 FGFR1 pathway EGFR pathway. Additionally, we delve into alternative potential targets that could offer new avenues LSCC. Lastly, summarize latest combined with checkpoint blockade (ICB) discuss prospects challenges this field.

Language: Английский

Citations

3
Prospect of targeting lysine methyltransferase NSD3 for tumor therapy DOI Creative Commons
Dan Li, Tiantian Tian,

Chung‐Nga Ko

et al.

Pharmacological Research, Journal Year: 2023, Volume and Issue: 194, P. 106839 - 106839

Published: July 1, 2023

Nuclear receptor binding SET domain protein 3 (NSD3) has recently been recognized as a new epigenetic target in the fight against cancer. NSD3, which is amplified, overexpressed or mutated variety of tumors, promotes tumor development by regulating cell cycle, apoptosis, DNA repair and EMT. Therefore, inhibition, silencing knockdown NSD3 are highly promising antitumor strategies. This paper summarizes structure biological functions with an emphasis on its carcinogenic cancer-promoting activity. The NSD3-specific inhibitors degraders also discussed reviewed this paper.

Language: Английский

Citations

4
Oncogene alterations in non-small cell lung cancer with FGFR1 amplification—novel approach to stratify patients who benefit from FGFR inhibitors DOI Open Access
Hidenori Kitai, Hiromichi Ebi

Translational Lung Cancer Research, Journal Year: 2024, Volume and Issue: 13(3), P. 684 - 688

Published: March 1, 2024

Language: Английский

Citations

0
NSD3::NUTM1 Fusion Sarcoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Prolonged Survival DOI Creative Commons
Jing Di,

Ali M. Alhaidary,

Chi Wang

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1709 - 1709

Published: Aug. 1, 2024

Nuclear Protein in Testis (NUT)-rearranged tumors comprise predominantly NUT carcinoma but also include certain lymphomas, leukemias, skin appendage tumors, and sarcomas. Although histologically diverse, all are genetically identified by oncogenic rearrangement the NUTM1 gene. Many fusion partners occur, NSD3 is carcinoma's third most common partner. Herein, we present a case of 26-year-old man with an

Language: Английский

Citations

0
Drug Discovery DOI
Manos C. Vlasiou

BENTHAM SCIENCE PUBLISHERS eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 16

Published: Oct. 9, 2024

Drug discovery is a complex process involving target identification, lead generation, and clinical development. Recent breakthroughs in genomics AI-driven approaches have expedited identification. Rational drug design advanced chemistry techniques improved compound optimization—preclinical testing benefits from organ-on-a-chip systems 3D cell culture models. Clinical development enhanced by personalized medicine innovative trial designs. Across all stages, big data, machine learning, AI play pivotal roles data analysis candidate selection. Collaboration between academia, industry, regulators fosters more efficient ecosystem. These advancements offer promising prospects for tackling challenging diseases enhancing global healthcare.

Language: Английский

Citations

0
THE ONCOGENIC ROLE OF THE NSD HISTONE METHYLTRANSFERASES IN HEAD AND NECK AND CERVICAL CANCERS DOI Creative Commons
Lavinia Ghiani, Susanna Chiocca

Tumour Virus Research, Journal Year: 2024, Volume and Issue: unknown, P. 200301 - 200301

Published: Dec. 1, 2024

Understanding the role of NSD proteins in virus-induced cancers could reveal new therapeutic strategies. Targeting may not only disrupt epigenetic changes triggered by viruses but also help restore normal cellular function. For instance, developing inhibitors counteract abnormal histone modifications caused viral infections and slow cancer progression. Our review on protein family emphasizes its critical regulation progression, cancers. As research molecular mechanisms advances, these are emerging as promising candidates for targeted therapies, particularly driven transcriptional dysregulation.

Language: Английский

Citations

0